CCR2 and renal cell carcinoma: Thus, several phase I/II clinical trials are in progress to assess the therapeutic effect of BMS-813160, a small molecule inhibitor of CCR2/5, in combination with Nivolumab and/or the tumor vaccine GVAX in several solid tumors including HCC, NSCLC, renal cell carcinoma (RCC) and pancreatic ductal adenocarcinoma (PDAC).